LifeBond, founded in 2007 by Ishay Attar and Orahn Preiss-Bloom, develops and manufactures medical devices for bio-surgery and tissue repair, intended to save lives and reduce post operative complications. The proprietary components of the company’s extensive product pipeline are distinctively comprised of 100% natural origin, bio-surgical materials with an established safety profile. LifeBond’s products combine the unique properties of bio-surgical implants with the regulatory benefits of medical devices, with simpler manufacturing processes and delivery as well as generally less expensive products.
LifeBond’s various products are tailored according to surgical need and designed to provide a range of deliverables, according to the respective surgical requirements. This includes products designed to prevent leakage from staple lines or resected organs, as well as products designed to provide control of bleeding and atraumatic fixation. By achieving one or more of these results after surgery, the goal is to create a wound site environment that supports the body’s natural healing and tissue repair processes.
The company’s first product, LifeSeal™ Surgical Sealant, is a CE marked product and the first surgical sealant intended in Europe for application in the entire gastro-intestinal tract to provide reinforcement and help reduce leaks. LifeSeal™ is designed to form a robust reinforcement layer to minimize post-operative complications such as staple-line leakage in colorectal procedures. Leakage rates, in colorectal procedures, can reach 15-19% and are associated with significant mortality and morbidity. As such, minimizing anastomotic leakage after colorectal resection presents an urgent clinical need. LifeSeal™ Surgical Sealant was evaluated in a multi-national, randomized-controlled clinical study in which the sealant was applied in high-risk low anterior resection (LAR) anastomosis procedures. Study results confirmed LifeSeal™’s safety and demonstrated a trend in anastomotic leak reduction as more than twice as often leaks were reported in patients with standard treatment compared to LifeSeal™ treated patients (8 vs. 3 leaks in 70 patients). Initial product commercialization in 2016 will take place in Europe.
The company’s second pipeline product, the LifeMesh™ Self-Fixating Mesh, is intended to provide secure surgical mesh fixation for hernia repair procedures. LifeMesh™ aims to provide atraumatic tissue fixation through its embedded adhesive layer. It is designed to reduce post surgical complications currently associated with penetrative mesh fixation (such as tacks or sutures). LifeBond’s proprietary production process provides the technology to transform nearly any commercial mesh into a self-fixating mesh. In the US alone, approximately 1M hernia repair procedures are performed annually.
The Company’s other products in development include tissue adhesives and absorbable hemostats.
LifeSeal™ is CE marked and available for commercial use in Europe. LifeMesh™ is an investigational device and has not yet been approved for sale in any market. Both LifeSeal™ and LifeMesh™ are limited by U.S. law to investigational use only.